Table 1.

Sensitization of human colon and breast cancer cell lines to doxorubicin and etoposide by KU-0060648

TreatmentSW620LoVoMCF7T47DMDA-MB-231
1 μmol/L Etop.4.7 ± 2.03.5 ± 0.523 ± 924 ± 416 ± 10
Etop. + KU0.05 ± 0.020.6 ± 0.23.1 ± 1.96.0 ± 1.74.1 ± 1.5
Fold enhancementa105 ± 166.6 ± 2.68.9 ± 4.94.1 ± 0.63.6 ± 1.2
100 nmol/L Dox.0.06 ± 0.061.4 ± 0.942.3 ± 139.0 ± 3.21.8 ± 0.6
100 nmol/L Dox. + KU0.004 ± 0.0020.03 ± 0.030.41 ± 0.080.19 ± 0.120.47 ± 0.14
Fold enhancement12 ± 873 ± 29107 ± 4358 ± 353.8 ± 0.6

NOTE: Cells were exposed to etoposide (Etop), doxorubicin (Dox), and/or KU-0060648 (KU, 1 μmol/L) for 16 hours before seeding for colony formation.

aEmbedded Image